Overview

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Status:
Completed

Trial end date:
2020-03-30

Target enrollment:

Participant gender:

Summary

A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction or maintenance treatment of anemia in subjects with incident DD-CKD.

Phase:

Phase 3

Details

Lead Sponsor:

Akebia Therapeutics

Treatments:

Darbepoetin alfa